A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
- Conditions
- HIV Infections
- Registration Number
- NCT00002236
- Lead Sponsor
- Pharmacia and Upjohn
- Brief Summary
The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.
- Detailed Description
Patients are divided into 2 treatment groups; the groups are balanced with respect to viral load. Group A receives ZDV, DLV, and IDV 3 times daily. Group B receives ZDV, DLV, and IDV 2 times daily. Patients are evaluated for changes from baseline in viral load and CD4 cell count.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 32
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (6)
AIDS Healthcare Foundation
🇺🇸Los Angeles, California, United States
UCSF AIDS Research Institute
🇺🇸San Francisco, California, United States
Saint Luke's - Roosevelt Hosp Ctr
🇺🇸New York, New York, United States
Anderson Clinical Research
🇺🇸Pittsburgh, Pennsylvania, United States
Univ of Tennessee / Div of Infect Dis / Dept of Med
🇺🇸Memphis, Tennessee, United States
Infectious Disease Physicians Inc
🇺🇸Annandale, Virginia, United States
AIDS Healthcare Foundation🇺🇸Los Angeles, California, United States